DexTech's phase IIb study for OsteoDex concludes with completed follow-up in spring 2020

2020-02-18


OsteoDex, the company’s phase 2b study for the treatment of advanced prostate cancer, so-called castration-resistant metastatic prostate cancer (mCRPC), will have complete follow-up for all patients at the end of April 2020, which concludes the phase II study. The results will be reported in May 2020. Interim results at today’s date are still very promising with significantly longer survival for patients who responded to treatment compared to the other patients. A handful of big pharma companies interested in OsteoDex have announced that they want to wait for the final results for patients’ survival, which will be reported to them in May 2020.

DexTech’s goal is to sign a license agreement regarding OsteoDex before the end of 2020.
The treatment of mCRPC has as a fundamental goal to be life-prolonging and preferably with acceptable side effects.

 "- We have full understanding that our interested parties want to see the final result of the follow up. I think we have very good possibilities to achieve the ultimate goal with the OsteoDex treatment," says CEO Anders R Holmberg.
 

For additional information:

Gösta Lundgren – CFO & Investor Relations

DexTech Medical AB

Telephone: +46 (0) 707104788

E-mail: gosta.lundgren@dextechmedical.com

 

This information is information that Dextech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on February 18, 2020.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful Phase II clinical study has been conducted with OsteoDex where the result shows high tolerability with mild side effects as well as efficacy and treatment effect on patients who fail on existing drugs. DexTech’s goal is to, after completing a phase II study, license each drug candidate. DexTech Medical AB is listed on the Spotlight Stock Market.


Se fullständiga pressmeddelande och andra nyheter från detta bolag hos Cision News